Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Clinical trial NCT07418190 · RECRUITING
Trial details
- NCT number
- NCT07418190
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2027-12-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.